医学
哮喘
药店
基本药物
私营部门
环境卫生
沙美特罗
公共卫生
家庭医学
慢性阻塞性肺病
公共部门
吸入性皮质类固醇
药方
传统医学
经济增长
护理部
经济
经济
内科学
精神科
作者
Obianuju B Ozoh,Joy Eze,Bilkisu Ilah Garba,O O Ojo,Elizabeth‐Martha Okorie,Esther S Yiltok,Chinyere Okoli,Ahmed Hammangabdo,David Beran
摘要
Abstract Objective(s) To determine the availability and affordability of asthma and COPD medicines across Nigeria. Methods This was a cross‐sectional survey conducted in 128 pharmacies (51 in public sector hospitals, 51 private sector community pharmacies and 26 charity or big private hospitals) across the six geopolitical zones of Nigeria using the WHO/Health Action Initiative method. The proportion of pharmacies where medicines were available, the median retail prices of originator and generics and affordability were analysed. A medicine was available if found in ≥ 80% of surveyed pharmacies. Unaffordability was defined as paying> 1 day’s wage (> US$1.68) for a standard 30‐day supply of the medicine. Results The available medicines were oral corticosteroids and oral salbutamol which are not on the WHO Essential Medicine List. Medicines were found more frequently in private than public pharmacies and in the southern than northern zones. Inhalable corticosteroid was not available at any public pharmacy nationwide. None of the EML medicines were affordable. The least number of days’ wages for a 30‐day supply of any inhalable corticosteroid‐containing medication was 3.5 days. Conclusions There are very limited availability and affordability of recommended asthma and COPD medicines across Nigeria with disparity across regions. Medicines that were available and affordable are not recommended and are harmful for long‐term use. This underpins the need for engagement of all stakeholders for the review of existing policies regarding access to asthma and COPD medicines to improve availability and affordability.
科研通智能强力驱动
Strongly Powered by AbleSci AI